Transcriptional changes in OXPHOS complex I deficiency are related to anti-oxidant pathways and could explain the disturbed calcium homeostasis  by Voets, A.M. et al.
Biochimica et Biophysica Acta 1822 (2012) 1161–1168
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isTranscriptional changes in OXPHOS complex I deﬁciency are related to anti-oxidant
pathways and could explain the disturbed calcium homeostasis
A.M. Voets a,b, M. Huigsloot c, P.J. Lindsey a, A.M. Leenders c, W.J.H. Koopman d, P.H.G.M. Willems d,
R.J. Rodenburg c, J.A.M. Smeitink c, H.J.M. Smeets a,b,e,⁎
a Department of Genetics and Cell Biology, Maastricht University, Maastricht, the Netherlands
b School for Cardiovascular diseases, Maastricht University, Maastricht, the Netherlands
c Nijmegen Center for Mitochondrial Disorders, Department of Pediatrics, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
d Department of Biochemistry (286), Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands
e School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands⁎ Corresponding author at: Department of Genetics
University, PO Box 616, 6200 MD Maastricht, the Nethe
E-mail address: bert.smeets@maastrichtuniversity.n
0925-4439/$ – see front matter © 2011 Elsevier B.V. All
doi:10.1016/j.bbadis.2011.10.009a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 August 2011
Received in revised form 20 September 2011
Accepted 11 October 2011
Available online 17 October 2011
Keywords:
Gene expression
Complex I deﬁciency
Mitochondrion
Oxidative stress
Selenoprotein
Nrf2Defective complex I (CI) is the most common type of oxidative phosphorylation disease, with an incidence of
1 in 5000 live births. Here, whole genome expression proﬁling of ﬁbroblasts from CI deﬁcient patients was
performed to gain insight into the cell pathological mechanism. Our results suggest that patient ﬁbroblasts
responded to oxidative stress by Nrf2-mediated induction of the glutathione antioxidant system and
Gadd45-mediated activation of the DNA damage response pathway. Furthermore, the observed reduced
expression of selenoproteins, might explain the disturbed calcium homeostasis previously described for
the patient ﬁbroblasts and might be linked to endoplasmic reticulum stress. These results suggest that
both glutathione and selenium metabolism are potentially therapeutic targets in CI deﬁciency.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria produce most of the cellular ATP through the pro-
cess of oxidative phosphorylation (OXPHOS). The OXPHOS system
is comprised of four multisubunit electron transport chain (ETC)
complexes (complexes I–IV) and the F0/F1-ATP-synthase (complex
V). Complex I (CI) is the largest of the OXPHOS complexes and one
of the entry points of electrons into the ETC. CI deﬁciency is the
most frequently encountered defect in mitochondrial energy metab-
olism [1] and is associated with e.g. Leigh and LHON disease, fatal
infantile acidosis, neonatal cardiomyopathy with lactic acidosis,
leucodystrophy with macrocep.haly and hepatopathy with renal
tubulopathy [2, 3]. Although children usually have a normal prenatal
development, symptoms start occurring during their ﬁrst year of life
after which the disease deteriorates rapidly and may become fatal
[4].
Disease-causing mutations have been described in both the mito-
chondrial DNA (mtDNA)-encoded (ND1 to ND6, and ND4L genes) and
nuclear DNA-encoded structural CI subunits (e.g. NDUFS1, NDUFS2,and Cell Biology, Maastricht
rlands. Tel.: +31 43 388 1995.
l (H.J.M. Smeets).
rights reserved.NDUFS4, NDUFS7, NDUFS8) and CI assembly factors (e.g. B17.2L,
NDUFA12L, C20ORF7) [5–26]. The cellular consequences of CI deﬁ-
ciency have been extensively studied in patient ﬁbroblasts. CI
deﬁciency leads to a slightly depolarized mitochondrial membrane
potential [27], increased reactive oxygen species (ROS) levels [28], in-
creased NAD(P)H levels [29], changes in mitochondrial morphology
[30] and disturbed calcium homeostasis [31, 32]. However, increased
ROS production and mitochondrial fragmentation was not always de-
tectable [33]. A ﬁrst study investigating transcriptional responses in
CI deﬁcient ﬁbroblasts cultured with glucose and galactose using a
mitochondria-targeted microarray detected the induction of metal-
lothioneins and heat shock proteins and the decreased expression
of mtDNA-encoded transcripts [34]. To get an unbiased overview of
the underlying pathological processes (not restricted to mitochon-
dria) in CI deﬁciency, we performed whole genome gene expression
and additional pathway analysis in ﬁbroblasts of a homogeneous
group of CI deﬁcient patients with a defect in one of the nuclear
encoded structural subunits. The CI deﬁciency might not stress the
cell to such an extent that relevant disease-associated gene expres-
sion changes can be picked up. Therefore, ﬁbroblasts were deprived
of glucose to stimulate energy production through oxidative phos-
phorylation. In galactose medium, the ﬂow of galactose to glucose-
1-phosphate is very slowwhich obliges cells to obtain ATP frommito-
chondrial oxidation of pyruvate and glutamine [35].
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2.1. Fibroblast cell lines
Fibroblasts were derived from skin biopsies of ﬁve patients homozy-
gous or compound heterozygous for nuclear complex I mutations and
ﬁve controls. The groups were matched for age and sex. All patients
have been described previously (#8807 see [26], #7898 see [24],
#5175 see [15], #6613 see [30], and #8382 see [25]). Table 1 provides
an overview of the subjects and physiological parameters in the patient
cell lines [4, 28, 29, 32]. The age- and sex-matched control group con-
sisted of four male subjects, ages 6 months (mo), 1 year (y) 7 mo, 1 y
6 mo, and 3 y 6 mo respectively and one female subject of 1 y 11 mo.
Fibroblasts were routinely cultured in medium 199 (Gibco, Paisley,
UK) supplemented with 10% fetal calf serum and penicillin/streptomy-
cin (respectively 100 U/ml and 100 μg/ml). To stimulate energy pro-
duction by oxidative phosphorylation, ﬁbroblasts were cultured in
galactose medium for 48 h. Galactose medium consisted of DMEM
without glucose, without pyruvate and with 4 mM L-glutamine (Invi-
trogen, Paisley, UK), 5.5 mM D-galactose (Sigma, Zwijndrecht, Nether-
lands), 1 mM uridine (Acros, Geel, BE), 10% dialyzed fetal calf serum
(Invitrogen) and penicillin/streptomycin. Glucose medium was identi-
cal to galactose medium except that D-glucose was present at 5.5 mM
instead of galactose. The stability of the mtDNA was preserved during
the course of the experiment in all cell lines under both conditions as
no mtDNA deletions or group/treatment speciﬁc differences in mtDNA
copy number (Supplementary Table 1) could be detected.
2.2. Microarray procedure
Total RNA was isolated using the TRIzol reagent (Invitrogen) and
puriﬁed with the RNeasy clean-up kit (Qiagen, Hilden, DE). RNA quan-
tity and purity were determined spectrophotometrically using the
Nanodrop ND-1000 (Nanodrop Technologies, Wilmington, DE, USA).
RNA integrity was assessed by determining the RNA 28S/18S ratio
using the Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA,
USA). Fibroblast RNA (150 ng) was reverse transcribed into cDNA and
ampliﬁed in a two-round ampliﬁcation reaction according to the man-
ufacturer's protocol (Affymetrix, Santa Clara, CA, USA). A mixture of
cDNA and added hybridization controls was hybridized on Affymetrix
HG-U133 Plus 2.0 chips, followed by staining and washing steps in the
GeneChip ﬂuidics station 400 (Affymetrix) according to the manufac-
turer's procedures. To assess the raw probe signal intensities, chips
were scanned using the GeneChip scanner 3000 (Affymetrix).
2.3. Microarray data analysis
Images of the Human Genome U133 Plus 2.0 arrays were quanti-
ﬁed with GCOS software (Affymetrix). The microarray data reported
in this manuscript have been deposited in NCBI Gene expressionTable 1
Patient characteristics and physiological cell line parameters.
Cell line Group Age Sex Affected subunit and mutation CI
8328 Patient 1 y M NDUFS1-211delE/V288A 24
8807 Patient 7 mo F NDUFS2–D445N 26
7898 Patient b7 mo M NDUFS4–R106X 36
5175 Patient 3 y M NDUFS7–V122M 68
6613 Patient b1 mo M NDUFS8–R94C 18
Physiological parameters have been published previously [4, 28, 29, 32]; values in bold are s
the protein level; CI=residual CI activity (% of lowest control); HEt=rate of ethidium form
methyl-2′,7′-dichloroﬂuorescein formation as a measure of ROS levels (% of control); GS
GSSG=oxidized glutathione levels (average control value 0.793±0.033 nmol/mg protein
peak=bradykinin(Bk)-induced peak in crease in cytosolic free Ca2+ concentration (% of con
(% of control); in previous publications, cell lines 8807, 7898 and 6613 correspond to cell lomnibus (GEO), accession number GSE27041. The chip description
ﬁle (CDF) used for the analysis was an update created and freely dis-
tributed by the microarray lab of the university of Michigan (http://
brainarray.mbni.med.umich.edu; [36]) based on Ensembl (version
10). A more detailed description of this analysis is shown in the sup-
plementary data. Brieﬂy, the genes were analyzed using Gaussian lin-
ear regression including the hybridization and labeling spikes, age,
sex, passage, copy number, and medium. The inference criterion
used for comparing the models is their ability to predict the observed
data, i.e. models are compared directly through their minimized
minus log-likelihood. When the numbers of parameters in models
differ, they are penalized by adding the number of estimated param-
eters, a form of the Akaike information criterion (AIC) [37]. For each
gene, the group was then added to the model. Then, the group-
medium interaction was also added to the model. The gene under
consideration was found to be differentially expressed if the AIC of
either of these two models decreased compared to the model con-
taining no group effect at all. The genes analyzed and fold changes
were loaded into the Pathvisio (version 2.0.8) [38] software package
to evaluate the transcripts in relation to known biological processes.
The gene database version “Hs_Derby_20090509” was used. Only
gene-transcripts with either their average intensities for the control
and patient groups above 150 or average intensities for one of these
groups above 300 and a 10% up or down regulation fold change
were used to obtain a ranked list of pathways with differentially
expressed genes. Pathvisio software was used to select the pathways
with a Z score larger than 1.96 and thus containing relatively high
numbers of differentially expressed genes.
2.4. Quantitative PCR
Differentially expressed genes were validated by real-time quanti-
tative PCR (qPCR) with the same RNA samples used for the micro-
arrays. Primers were designed using the NCBI Primer-BLAST tool
(NCBI home page; http://www.ncbi.nlm.nih.gov/). cDNA was pre-
pared from 1 μg of RNA in a standard reverse transcriptase reaction.
PCR was performed in a 7900HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) using SensiMixPlus SYBR (Quantace,
Finchley, UK). Cycling conditions were: an initial step of 2 min at
50 °C, activation of the polymerase at 95 °C for 10 min, and 40 cycles
of 15 s at 95 °C followed by 1 min at 60 °C. The TATA-box binding pro-
tein (TBP) gene was used as an internal reference. Genes for which
QPCR was performed and the primers used for ampliﬁcation are listed
in Supplementary Table 2. Results were analyzed using Gaussian line-
ar regression, similar to the microarray analysis. The housekeeping
gene (TBP), age, sex, passage, copy number, rin, and mediumwere in-
cluded during the analysis. The AIC was used to assess whether there
was a difference between the controls and patients (group effect). All
statistical analyses presented were performed using the freely avail-
able program R [39] and the publicly available library ‘growth’[40].HEt CM-H2DCF GSH GSSG ERCa [Ca]C peak [Ca]M peak
N/A N/A N/A N/A N/A N/A N/A
191 244 N/A N/A 82 91 87
174 187 18.8 0.587 77 84 79
151 212 21.3 0.630 73 80 76
222 275 28.5 1.017 85 91 89
igniﬁcantly different from control (see respective publications); mutations are given at
ation as a measure of ROS levels (% of control); CM-DCF=rate of 5-[and −6]-chloro-
H=reduced glutathione levels (average control value 26.1±1.8 nmol/mg protein);
); ERCa=resting calcium content of the endoplasmic reticulum (% of control); [Ca]C
trol); [Ca]M peak=Bk-induced peak increase in mitochondrial free Ca2+ concentration
ines 7276, 5260 and 6603 respectively; m=male, f=female, N/A=not available.
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Protein expression was monitored by Western blot analysis of 12%
SDS-PAGE gels loaded with 40 μg of whole cell extract. The following
primary antibodies were used: Complex I (NDUFA9; Mitosciences,
Oregon, USA), HMOX1 (Abcam, Cambridge, UK), GCLM (Sigma), GSR
(Santa Cruz, Heidelberg, DE), and TrxR1 (Santa Cruz). Complex II
(70 kDa Fp; Mitosciences) was used as a loading control. Secondary
antibodies used were polyclonal goat anti-mouse IgG/HRP (Dako,
DK) and immunoPure goat anti-rabbit IgG/peroxidase (Pierce Bio-
technology, Rockford, IL, USA). Detection of the signal was performed
using ECL Western Blotting Substrate (Thermo Scientiﬁc, Amsterdam,
NL) following the manufacturer's instructions.
3. Results
Global gene expression proﬁles of ﬁbroblast cell lines from ﬁve CI
deﬁcient patients with a mutation in a nuclear CI gene were charac-
terized in glucose and galactose medium to identify processes in-
volved in pathogenesis, novel biomarkers for CI deﬁciency and
potential future targets for therapeutic interventions. In order to
gain insight into the changes in essential cellular processes rather
than single genes, genes were clustered based on cellular function
and analyzed by pathway analysis using Pathvisio software [38].
3.1. Gene expression analysis
In total, disease state, culture condition and their interaction sig-
niﬁcantly altered the expression of 3279 genes. The disease stateTable 2
Pathway analysis results.
Patients versus controls
glucose
Patie
galac
Pathway % changed Z score % cha
Changes due to culture condition only
Cholesterol biosynthesis 14.29 0.53 14.29
Proteasome degradation 13.33 0.85 25.00
Prostaglandin synthesis and regulation 13.33 0.60 20.00
Changes due to disease, notable in normal condition
Pentose phosphate pathway 57.14 4.15 42.86
Heme biosynthesis 44.44 3.43 33.33
Alanine and aspartate metabolism 33.33 2.69 33.33
Urea cycle and metabolism of amino groups 26.32 2.36 31.58
Ganglio sphingolipid metabolism 26.67 2.14 33.33
Adipogenesis 15.70 2.10 23.14
Changes due to disease, notable in normal and selective condition
Senescence and autophagy 22.58 4.07 27.96
Selenium 17.57 2.17 29.73
Mismatch repair 33.33 2.32 44.44
Nucleotide metabolism 27.78 2.51 38.89
Changes due to disease that interact with culture condition
Oxidative stress 22.22 2.11 48.15
Selenium metabolism/selenoproteins 28.13 3.41 40.63
TGF beta signaling pathway 19.23 2.22 34.62
Translation factors 21.43 2.46 26.19
Changes due to interaction disease-culture condition only
Cell cycle 14.12 1.26 32.94
G1 to S cell cycle control 12.31 0.61 27.69
Androgen receptor signaling pathway 8.41 −0.57 25.23
Glutathione metabolism 6.25 −0.51 37.50
Keap1–Nrf2 7.69 −0.28 46.15
DNA damage response 11.94 0.52 31.34
Glycogen metabolism 11.43 0.27 31.43
TGF-beta receptor signaling pathway 10.27 0.09 22.60
Id signaling pathway 6.12 −0.92 22.45
TNF-alpha/NF-κB signaling pathway 8.00 −0.93 20.00
Every pathway counts at least 7 genes measured by the microarray.
A Z score of more than 1.96 indicates that a pathway is signiﬁcantly changed (shown in boinduced fold changes between 0.08 and 6.89 (of which 79% between
0.66 and 1.5 (b50% change)) in the glucose condition and between
0.08 and 12.18 (69% between 0.66 and 1.5) in the galactose condition.
Furthermore, the different culture conditions caused gene expression
changes of 0.32 to 2.91 (90% between 0.66 and 1.5) and 0.11 to 29.74
fold (46% between 0.66 and 1.5) in controls and patients respectively.
Pathway analysis was performed to identify processes that were
altered due to the cumulative effect of differentially expressed
genes (Table 2 and Supplementary Table 3). The sum of the differen-
tially expressed genes in a pathway can lead to increased expression,
decreased expression or a miscellaneous effect (both inhibition and
stimulation), which is indicated for each pathway.
3.1.1. Changes due to culture condition only
The metabolic switch due to glucose deprivation of the cells in ga-
lactose medium changed the expression of 2888 genes. This included
genes with a larger/smaller fold change or an opposite fold change in
patients compared with controls. If only genes were included that
showed the same effect on galactose compared with glucose for
both groups, 1304 genes were changed and these could be mapped
to the pathways cholesterol biosynthesis (increased in galactose),
proteasome degradation (miscellaneous effect) and prostaglandin
synthesis and regulation (increased in galactose) (Fig. 1B).
3.1.2. Changes due to complex I deﬁciency
Between patients and controls, 1407 and 2335 genes were signif-
icantly changed in glucose and galactose, respectively, with an over-
lap of 1199 genes. Pathways that showed a signiﬁcant change only
in the normal glucose condition included the pentose phosphatents versus controls
tose
Galactose versus glucose
identical in patients and
controls
Galactose versus glucose
different in patients and
controls
nged Z score % changed Z score % changed Z score
−0.32 57.14 5.92 0.00 −1.34
1.53 18.33 2.20 15.00 0.89
0.36 23.33 2.47 6.67 −0.81
1.76 28.57 1.65 14.29 0.24
1.25 22.22 1.24 0.00 −1.08
1.44 25.00 1.75 8.33 −0.33
1.61 31.58 3.17 10.53 −0.12
1.61 33.33 3.04 6.67 −0.57
1.65 11.57 0.62 12.40 0.36
2.68 15.05 1.68 13.98 0.80
2.78 9.46 −0.13 17.57 1.70
2.12 11.11 0.12 22.22 1.03
2.39 22.22 1.75 22.22 1.45
4.20 14.81 0.85 37.04 4.22
3.45 15.63 1.08 28.13 3.00
3.26 11.54 0.39 26.92 3.56
1.48 19.05 1.99 21.43 2.07
3.78 10.59 0.21 24.71 3.92
2.17 9.23 −0.19 21.54 2.61
2.12 6.54 −1.19 21.50 3.35
2.10 0.00 −1.33 37.50 3.30
2.72 15.38 0.66 38.46 3.08
3.00 11.94 0.56 23.88 3.26
2.17 14.29 0.87 25.71 2.69
1.64 10.96 0.43 17.12 2.24
0.91 10.20 0.07 20.41 2.01
0.88 8.57 −0.61 16.00 1.98
ld).
pentose phosphate pathway
heme biosynthesis
alanine and aspartate metabolismGlucose only
A
urea cycle and metabolism of amino acids
ganglio sphingolipid metabolism
adipogenesis
senescence and autophagy
Control CI deficient
selenium
mismatch repair
nucleotide metabolism
oxidative stress
selenoproteins
TGF beta
cell cycle
androgen receptor signaling
glutathion metabolism
Keap1-Nrf2Galactose only
DNA damage response
glycogen metabolism
Control only translation factors
B
Glucose Galactose
cholestrol biosynthesis
proteasome degradation
prostaglandin synthesis and
regulation
CI deficient only TGF beta receptorId
TNF alpha/NF-kB
Fig. 1. Pathways signiﬁcantly different (A) in controls and patients and (B) in glucose and galactose conditions. Pathways in the box are changed in both culture conditions (A) or
groups (B). Pathways above and below the box are only changed in the indicated condition (A) or group (B). Arrows indicate increased or decreased expression; for pathways with-
out arrow, the direction of the change is not clear.
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patients), alanine and aspartate metabolism (increased in patients),
urea cycle and metabolism of amino groups (increased in patients)
and ganglio spingolipid metabolism (decreased in patients). Further-
more, some pathways were signiﬁcantly altered in both normal
glucose and galactose condition: senescence and autophagy (miscel-
laneous effect), selenium (decreased in patients), mismatch repair
(decreased in patients) and nucleotide metabolism (increased in
patients) (Fig. 1A).
3.1.3. Changes due to disease and interacting with the culture condition
There were 1584 genes that differed between patients and con-
trols in the glucose and/or galactose culture condition, but for which
patients showed a different response to the galactose condition com-
pared with the controls. A different response could be a response to
galactose in only the patients or the controls, a quantitative difference
or an opposite effect. When considering these genes, part of them
were altered as a result of the CI deﬁciency, but additionally showed
an interaction between this deﬁciency and the culture condition. Al-
tered pathways included oxidative stress (increased in patients and
further increased in galactose medium), selenium metabolism and
selenoproteins (decreased in patients and further decreased in galac-
tose medium), the TGF beta signaling pathway (miscellaneous effect)
and translation factors (decreased in patients). The remainder of
the genes was only altered in patient cells relative to control cells
on galactose medium but not in glucose medium. This last group of
genes was mapped to pathways involved in cell cycle progression
(decreased in patients), oxidative stress (increased in patients;
Keap1–NRF2, glutathione metabolism, DNA damage response) andsignaling (miscellaneous effect; androgen receptor, TGF beta recep-
tor, Id, TNF alpha/NF-κB). A general overview of all signiﬁcantly
changed pathways is shown in Fig. 1.
3.2. QPCR and western blot validation of microarray data
From the pathway analysis, representative genes with fold
changes of more than 50% were selected and validated by QPCR
(Table 3). For all except one gene (C-MYC), the QPCR method
detected a difference between patients and controls comparable
with the microarray analysis. Furthermore, to correlate gene expres-
sion and protein levels, western blot analysis was performed for pro-
teins selected from the genes with relatively high gene expression
fold changes in signiﬁcantly altered pathways for patients versus con-
trols in galactose medium. Signiﬁcantly increased expression was
conﬁrmed for HMOX and GCLC, a similar trend in protein expression
was observed for TXNRD1 but no change was detected for GSR
(Fig. 2). Additionally, western blot analysis also revealed that com-
plex I deﬁciency in the cell lines was accompanied by reduced protein
levels of complex I (Fig. 2).
4. Discussion
During the last decade, studies have generated extensive knowl-
edge on the pathogenesis of CI deﬁciency [4, 28, 29, 32]. In spite of
these advances in physiological, biochemical and genetic insights,
the total picture is far from complete. In the present study, gene
expression analysis was performed for a more general overview of
the processes involved in CI deﬁciency in ﬁbroblasts. According to
Table 3
Selected genes for the QPCR signature.
Disease effect Medium effect
Gene
symbol
Glucose
condition
Galactose
condition
Controls Patients
Array QPCR Array QPCR Array QPCR Array QPCR
Keap1–Nrf2
NRF2 0.77 1.30 1.42 0.82 0.77 1.25 1.42
KEAP1 0.77 1.28 1.27 1.68 1.58
Oxidative stress
CYBA 0.56 0.63 0.56 0.62 0.63 0.62
FOS 0.44 0.48 1.55 2.10 0.62 2.19 2.85
HMOX1 7.23 17.58 9.76 28.95
Glutathione metabolism
GSR 1.96 2.46 2.31 3.23
IDH1 1.50 1.79 1.27 1.88 2.61
GCLC 1.90 1.82 2.38 2.66
GCLM 1.94 2.67 1.91 2.81
Selenium metabolism/selenoproteins
SELK 2.14 2.30 2.01 2.36
SEPP1 0.38 0.33 0.21 0.33 0.59 0.39 0.32 0.39
Pentose phosphate pathway
PGD 1.75 1.55 2.10 2.36
DNA damage response
GADD45A 1.86 2.25 3.20 1.89 2.08
GADD45B 1.71 3.56 3.40 3.56 1.81 1.84 1.81
TNFRSF10B 2.05 1.69 2.12 2.11
C-MYC 1.90 1.78 1.75 1.78
Cell cycle–anaphase regulation
ESPL1 0.60 0.35 1.69 2.04
CDC20 0.48 0.38 0.48 2.55
Nucleotide metabolism
PRPS1 1.77 1.79 0.59 0.50 0.29
Glycogen metabolism
GBE1 0.87 1.43 1.74 1.63 1.70
Senescence and autophagy
ING1 0.71 1.60 1.91 1.69
TGF beta signaling pathway
LTBP1 1.70 0.60 0.23 1.97 0.44 0.54
TGIF 1.46 1.65 1.71 2.60
Adipogenesis
RORA 1.49 1.86 2.59 1.84 2.41
DDIT3 2.61 2.50 1.65 2.24 3.46
LMNA 0.45 0.44 0.45 0.46
ADFP 0.66 1.41 1.95 1.84
Genes in italics did not show an interaction between disease effect and medium effect
with QPCR analysis (in contrast to microarray analysis) but are still able to distinguish
patients from controls in both culture media.
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mutations in structural CI subunits of the dehydrogenase and hydrog-
enase modules of the hydrophilic peripheral arm of complex I pro-
truding in the matrix. These modules are involved in oxidation of
NADH to NAD+ and electron transfer to ubiquinone [41] and muta-
tions in their proteins disturb these ﬂuxes, leading to CI deﬁciency.
Therefore, we consider these patients as a group with a common
pathophysiological basis, making them suitable fro genome-wide
gene expression approaches.
Differential expression of a number of genes and proteins in rele-
vant pathways was validated and related to available physiological
and biochemical data.
4.1. Experimental set-up
To be able to examine the consequences of CI deﬁciency in ﬁbro-
blasts (which are mainly glycolytic), cell lines were challenged to
use their OXPHOS system for energy production by culturing in galac-
tose medium in the absence of glucose [33, 34]. Our analytical model
corrected for a number of potential ‘noise’ factors (biological e.g. age,
sex and passage; technical e.g. chip effect), in contrast to a previous
study [34]. The approach differed further from this study [34] bytype and scope of the array (Affymetrix GeneCHIPS versus home-
made two-color cDNA microarrays with selected mitochondria-
related genes). The current study provides a well-controlled and
more complete picture of the molecular processes in ﬁbroblasts of
CI patients. These differences can explain why only eleven genes
showing differential expression in the previous study could be con-
ﬁrmed [34] (Supplementary Table 4). Unfortunately, nine additional
genes could not be analyzed due to the use of the more accurate
updated probe set deﬁnitions [36] and thirteen genes had low signal
intensities, which made comparison impossible. However, the eleven
conﬁrmed results included multiple metallothionein transcripts,
which were key elements in the previous study [34].
4.2. General gene expression analysis results
Linear regression analysis showed signiﬁcantly altered expression
of in total 3279 genes due to disease, culture medium or a combina-
tion of both. As expected, gene expression differences were the high-
est when comparing patient and control cells cultured in galactose
medium and when comparing the glucose and galactose condition
in patient ﬁbroblasts. Both the number of differentially expressed
genes and the expression difference were higher. In control cells,
less than 10% of the differentially expressed genes showed fold
changes of more than 50% in galactose compared with glucose indi-
cating that control cells were better capable of handling the galactose
challenge. The altered expression of a number of genes was validated
by QPCR and all of these, except for one gene (C-MYC), showed a
response similar to the microarray thus conﬁrming the overall reli-
ability of the microarray data. Furthermore, for two genes, increased
gene expression was accompanied by increased protein expression,
validating the biological relevance of the detected differences in
gene and pathway expression.
4.3. Differentially expressed processes
To identify processes that were altered due to the cumulative
effect of differentially expressed genes in such a process, pathway
analysis was performed. Pathways that were only changed in patient
versus control ﬁbroblasts both cultured in the presence of glucose
were mainly involved in metabolism and included in most cases
only a small number of genes with limited fold changes. This suggests
that under glycolytic conditions, ﬁbroblasts can adapt relatively easily
to alternative energy sources. Therefore, we focused on processes that
were changed due to the combination of disease and galactose cultur-
ing when the cells are forced to use their oxidative phosphorylation
system.
4.3.1. Oxidative stress
Although the oxidative stress pathway was signiﬁcantly changed
when comparing patient and control cells on glucose, the difference
was more signiﬁcant (higher Z score) and more genes were involved
on galactose medium. This is consistent with the observation of in-
creased ROS levels in the CI deﬁcient ﬁbroblasts (Table 1; [4, 28]).
Furthermore, in an independent study with ﬁbroblasts from OXPHOS
(including CI deﬁcient) patients, we observed higher ROS levels
when ﬁbroblasts (including controls) were cultured with galactose
compared with glucose (manuscript in preparation). Transcripts of
genes involved in glutathione homeostasis were increased, but tran-
scription of the other antioxidant enzymes, catalase and superoxide
dismutase (mitochondrial and extracellular), was decreased. Al-
though enzyme activity measurements should conﬁrm these results,
this suggests that the glutathione antioxidant system is the main de-
fense mechanism counterbalancing increased ROS production in CI ﬁ-
broblasts. Additionally, the induction of the DNA damage response
through increased expression of GADD45A and GADD45B could fur-
ther emphasize cellular stress. Gadd45-mediated growth arrest [42]
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Fig. 2.Western blot validation of mRNA results. (A) Original western blot results and (B) a graphical representation of differences in protein levels for complex I (CI), HMOX, GSR,
GCLC and TXNRD1 between control (white bars) and patient (grey bars) ﬁbroblasts cultured with galactose medium, normalized for the expression in controls (* pb0.05 patients
versus controls galactose). Complex II (CII) was used as a reference. In panel C, microarray, QPCR and western blot results for these genes in patients versus controls in galactose
medium were compared.
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Fig. 3. Activation of the KEAP1–NRF2 pathway in patient ﬁbroblasts culturedwith galactose.
Fold changes of the signiﬁcantly changed genes (patients versus control culturedwith galac-
tose) are shown in bold italics.
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slower rate than healthy control ﬁbroblasts.
A number of redox-sensitive genes that were signiﬁcantly chan-
ged in this study (HMOX1, CAT and SOD3) were not reported in a pre-
vious study [34], most likely due to a different analytical approach.
However, the induction of a number of metallothionein genes was
detected in both studies (Supplementary Table 4). Metallothioneins
are considered potent antioxidants of which the expression is in-
duced by ROS, heavy metals and other forms of cellular stress [34].
Another study with different genetically characterized CI deﬁcient pa-
tient ﬁbroblast cell lines (NDUFV1 p.W51X+p.T423M and NDUFA1
p.R37S+G8R) did not detect differences in catalase and glutathione
reductase protein expression and only one of the three patient cell
lines showed the induction of mitochondrial superoxide dismutase
protein [33]. This could be explained by the fact that, in contrast to
our cell lines (Table 1; [4, 28]), their cell lines did not show increased
ROS production, explaining the lack of increased antioxidant defense.
It also suggests that the CI mutations of these patients might have
different consequences than the ones studied here.
4.3.2. KEAP1–NRF2–glutathione
One of the most obvious differentially expressed pathways was
the KEAP1–NRF2 pathway, leading to the activation of a large number
of genes involved in glutathione homeostasis and the thioredoxin and
peroxiredoxin antioxidant defense (Fig. 3). ROS-mediated modiﬁca-
tion of cysteine (Cys) residues in Keap1 is known to result in dimin-
ished binding of Nrf2, leading to decreased Nrf2 degradation, its
translocation to the nucleus and transcription of genes containing
the antioxidant response element (ARE) in their promoter region
[43, 44]. Activation of NRF2 signaling was described previously inﬁbroblasts of patients with a mutation in the mitochondrial ATP6
gene [45]. Consistent with a lack of NRF2 signaling, glutathione levels
in patient ﬁbroblasts were not signiﬁcantly different from controls in
de glucose situation (Table 1; [29]). However, reduced glutathione
(GSH) levels of cell lines 7898 and 5175 were at the lower limit of
control values and oxidized glutathione (GSSG) levels were at the
higher limit of control values for cell line 6613 [29]. It has been sug-
gested previously that antioxidants present in the culture medium
may quench ROS [46], which might make up-regulation of the antiox-
idants unnecessary. With the induction of glutathione homeostasis
genes, it can be expected that glutathione levels are increased in
the galactose situation to buffer the additional free radicals and pre-
vent oxidative damage. Up-regulation of GCLC was conﬁrmed at the
protein level.
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Pathway analysis revealed signiﬁcant differences in the expression
of the selenium (metabolism) and selenoprotein genes in control and
patient ﬁbroblasts. Although some overlap exists between these
pathways and the oxidative stress pathway, the functions of many
of the selenoproteins are unknown [47]. Selenoproteins are a group
of proteins that contain selenocystein as an integral part of their poly-
peptide chain and include different protein families such as the thior-
edoxin reductases (TXNRDs) and glutathione peroxidases (GPXs),
and a number of alphabetically annotated selenoproteins (SelK,
SelM, SelN…) [47, 48]. While some classes are deﬁnitely involved in
antioxidant pathways (GPXs) and redox pathways (TXNRDs), others
have been implicated to play a role in calcium homeostasis (SelN)
[47]. Recently, it was shown that association of SelN with the ryano-
dine receptor was necessary to control release of calcium from intra-
cellular endoplasmic reticulum stores [49]. Thus, a decrease of SEPN1
transcripts, might correlate with the decreased calcium ﬂuxes mea-
sured in the studied patient cell lines (Table 1; [31, 32]). If conﬁrmed
this might provide a new lead in the pathogenesis of CI deﬁciency. In
HepG2 cells, SelK was induced by endoplasmic reticulum stress and
protected the cells from stress induced apoptosis [50]. The increased
mRNA expression of TXNRD1 and SelK, opposed to the decreased
expression of multiple other selenoproteins, might suggest the pref-
erential expression of selenoproteins involved in stress reduction in
oxidative CI deﬁcient patient ﬁbroblasts. The expression of selenopro-
teins is depending on the cellular selenium status [51]. Selenium
deﬁciency has been shown to induce the expression of Nrf2 target
genes [51, 52], providing a link between the observed induction of
the Keap1–Nrf2 pathway and the decreased expression of selenopro-
teins. Therefore, monitoring and adjusting selenium levels might be
beneﬁcial for patients with complex I deﬁciency. Dietary selenium
has been supplemented for the treatment or prevention of cancer
[53] and Alzheimer's disease [54]. This study emphasizes the rele-
vance of testing the applicability and efﬁciency of selenium supple-
mentation also for CI deﬁciency, which should be tested ﬁrst in vitro
and in animal models and later in clinical trials.
5. Conclusion
The gene expression analysis supports the changes in oxidative
stress levels previously measured in ﬁbroblasts of CI deﬁcient patients.
It was shown that the cells adapt to and protect themselves against a
higher oxidative state through transcriptional regulation of the NRF2
pathway. Additionally, altered expression of selenoproteins provided
a new way to explain diminished calcium ﬂuxes in the CI deﬁcient
ﬁbroblasts. Altogether, the glutathione and selenium pathways might
be considered as (new) targets for future therapeutic interventions.
Extending our approach to other CI deﬁcient patient groups with
functionally different defects (assembly factor or mtDNA defects affect-
ing the CI proton translocation) in different genes will elucidate if
the mechanisms identiﬁed are common to all complex I patients or if
heterogeneity of pathophysiological processes exist.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbadis.2011.10.009.
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